|Bid||0.0000 x 4000|
|Ask||0.0000 x 2900|
|Day's Range||3.4500 - 3.6300|
|52 Week Range||1.5600 - 4.1400|
|Beta (3Y Monthly)||0.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.95|
Option Care Health Inc. , the nation’s largest independent national provider of home and alternate site infusion services, today announced that John Rademacher, Chief Executive Officer, will participate in a fireside chat on September 10 at the Morgan Stanley Global Healthcare Conference, scheduled to start at 10:00 a.m.
The Providence Service Corporation (the “Company” or “Providence”) (PRSC) today announced that it has appointed Kathryn Stalmack to serve as Senior Vice President, General Counsel and Corporate Secretary of Providence and its subsidiary, LogistiCare Solutions, LLC (“LogistiCare”). Ms. Stalmack will be responsible for all legal matters relevant to the Company including contracting, litigation, corporate governance and regulatory compliance. Ms. Stalmack succeeds M. Chinta Gaston, who is retiring and previously served Senior Vice President, General Counsel and Secretary of Providence since January 2019 and served as LogistiCare’s General Counsel since 2003.
Denver-based BioScrip has merged with its competitor, Option Care Enterprises Inc. to form a new combined company, Option Care Health Inc. The new company will be the largest independent home and alternate site infusion services provider in the U.S. The company specializes in providing intravenous services to patients either in their home or at its own facilities, which it has in 46 states. The two companies were competitors, but had some complementary features, CEO John Rademacher told Denver Business Journal. Rademacher came from the legacy Option Care side and will serve as CEO of the new combined company.
Option Care Health, Inc. (BIOS) announced today that on August 7, 2019, it received a letter from the Nasdaq Staff informing it that, since the merger between Option Care Enterprises, Inc. and BioScrip, Inc. constituted a change of control for purposes of the Nasdaq Listing Rules, Option Care was required to meet all applicable criteria for initial listing on The Nasdaq Global Select Market. The letter indicated that, since Option Care did not satisfy the minimum $4.00 bid price requirement upon consummation of the merger, Option Care’s securities were subject to delisting unless it requests a hearing before the Nasdaq appeals panel, which will allow Option Care to remain listed pending the outcome of the hearing. As part of its preparations for the merger, Option Care anticipated receiving the Staff’s letter and plans to request a hearing before the appeals panel, which will allow Option Care to continue to remain listed on Nasdaq until the issuance of the panel’s decision.
With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.
Option Care Enterprises, Inc. (“Option Care”) and BioScrip, Inc. (“BioScrip”) today announced the successful completion of their merger, which follows the satisfaction of the transaction’s closing conditions, including approval by BioScrip shareholders and the receipt of all necessary regulatory approvals. The newly combined company, Option Care Health, Inc. (“Option Care Health” or the “Company”), emerges as the largest independent home and alternate site infusion services provider in the United States.
BioScrip’s merger with Option Care is expected to close on or about August 6, 2019. BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,100 teammates and nearly 70 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting.
BioScrip (BIOS) delivered earnings and revenue surprises of -30.00% and 3.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
DENVER, July 30, 2019 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions,.
BioScrip, Inc. (BIOS) ("BioScrip"), the largest independent national provider of infusion and home care management solutions, today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”), leading independent proxy advisory firms, recommend that BioScrip stockholders vote “FOR” the proposals that are conditions to the proposed merger with Option Care, at the special meeting of stockholders to be held on August 2, 2019. BioScrip’s Board of Directors encourages stockholders to vote “FOR” each of the proposals relating to the combination with Option Care. The merger is expected to close in early August 2019 after the special meeting of stockholders.
The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]
NEW YORK, June 26, 2019 -- Halper Sadeh LLP, a global investor rights law firm, announces the filing of shareholder class action lawsuits against BioScrip, Inc. (NASDAQ: BIOS),.
The Providence Service Corporation (“Providence”) (PRSC) and its subsidiary, LogistiCare Solutions, LLC (“LogistiCare”), today announced that effective immediately R. Carter Pate will serve as Interim Chief Executive Officer of LogistiCare. Mr. Pate will continue his duties as Providence’s Interim CEO and assumes the responsibilities of Jeff Felton, who has resigned as CEO of LogistiCare effective immediately. Mr. Pate will remain as Interim CEO of Providence and LogistiCare until December 31, 2019. Over the next six months, Mr. Pate will work with Providence’s Board of Directors to conduct a search internally and externally to identify a permanent CEO for the combined business. Carter Pate is the Founder and Chief Executive Officer of Carter Pate, LLC, a consulting firm he founded in 2014. Since 2017 he has served as the Interim CEO of Providence Service Corporation (PRSC).
NEW YORK , June 21, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
Dan Greenleaf, President and Chief Executive Officer of BioScrip, will become Special Advisor to the newly combined company’s Board Chairman, Harry Kraemer, and Chief Executive Officer, John Rademacher. Mr. Greenleaf will provide strategic and operational counsel to ensure a smooth transition, optimize the integration of both companies, and drive long-term growth opportunities.
Adds Accomplished Independent Director R. Carter Pate to Board and Audit Committee Announces Retirement of Director, James P. Evans, Chair of the Board’s Nominating and.
Given BioScrip’s pending combination with Option Care, Option Care’s Chief Executive Officer, John Rademacher, and Chief Financial Officer, Mike Shapiro, plan to accompany BioScrip’s senior leadership at these events. A live webcast of the Jefferies group presentation and copies of the materials presented can be accessed via BioScrip’s Investor Relations website at https://investors.bioscrip.com/ or through the following link: http://wsw.com/webcast/jeff118/bios/.
Moody's Investors Service ("Moody's") today upgraded the Corporate Family Rating (CFR) of BioScrip, Inc. ("BioScrip") to B3 from Caa1 and upgraded the Probability of Default to B3-PD from Caa1-PD. At the same time, Moody's upgraded the Speculative Grade Liquidity Rating to SGL-3 from SGL-4 and assigned a B2 (LGD 3) rating to the proposed $925 million First Lien Term Loan B. The outlook is stable. The upgrade reflects the improvement in BioScrip's credit profile due to the pending merger with HC Group Holdings III, Inc. (dba Option Care).
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the fourth quarter, which unveil their equity positions as of December 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
NEWTOWN SQUARE, Pa., May 03, 2019 -- Kaskela Law LLC announces that it is investigating BioScrip, Inc. (“BioScrip” or the “Company”) (Nasdaq: BIOS) on behalf of the Company’s.